VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ADPT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ADPTAdaptive Biotechnologies Corporation
$28.46$4.6B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksADPTFinancials

Adaptive Biotechnologies Corporation (ADPT) Income Statement

9Y historyFree accessUpdated daily

Revenue grew from $43.2M to $83.9M and gross margin reached 76.2%, yet trailing operating margin of -20.6% and net margin of -21.5% suggest profitability claims warrant reconciliation before being relied upon.

Income StatementBalance SheetCash FlowRatios

ADPT Income Statement

Annual statement

ADPT Income Statement

Adaptive Biotechnologies Corporation (ADPT) annual income statement — 9-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Sales/Revenue298.01M276.98M178.96M170.28M185.31M154.34M98.38M85.07M55.66M38.45M
Revenue Growth %17.91%54.77%5.1%-8.11%20.06%56.88%15.65%52.83%44.77%-
Cost of Goods Sold77.45M71.36M72.08M75.55M57.91M49.3M22.53M22.27M19.67M15.68M
COGS % of Revenue-25.76%40.28%44.37%31.25%31.94%22.9%26.18%35.33%40.78%
Gross Profit220.56M205.62M106.88M94.72M127.4M105.04M75.85M62.8M35.99M22.77M
Gross Margin %74.01%74.24%59.72%55.63%68.75%68.06%77.1%73.82%64.67%59.22%
Gross Profit Growth %-92.39%12.83%-25.65%21.28%38.48%20.79%74.46%58.09%-
Operating Expenses268.76M262.74M269.43M321.76M327.58M314.01M228.67M141.19M85.75M66.4M
OpEx % of Revenue-94.86%150.55%188.96%176.78%203.45%232.43%165.96%154.05%172.71%
Selling, General & Admin184.31M167.27M157.56M172.51M184.13M169.97M110.89M68.78M44.9M32.71M
SG&A % of Revenue-60.39%88.05%101.31%99.36%110.12%112.72%80.86%80.66%85.09%
Research & Development83.18M93.77M102.95M122.12M141.76M142.34M116.07M70.7M39.16M32M
R&D % of Revenue-33.85%57.53%71.72%76.5%92.22%117.98%83.11%70.35%83.22%
Other Operating Expenses1.28M1.7M8.91M27.13M1.7M1.7M1.7M1.7M1.7M1.69M
Operating Income-48.21M-57.12M-162.55M-227.03M-200.19M-208.97M-152.82M-78.39M-49.76M-44.48M
Operating Margin %-16.18%-20.62%-90.83%-133.33%-108.03%-135.39%-155.33%-92.15%-89.39%-115.68%
Operating Income Growth %-64.86%28.4%-13.41%4.2%-36.74%-94.94%-57.55%-11.87%-
EBITDA-32.87M-39.29M-143.29M-204.8M-179.27M-195.01M-144.34M-70.6M-43.76M-38.68M
EBITDA Margin %-11.03%-14.19%-80.07%-120.28%-96.74%-126.35%-146.72%-82.99%-78.61%-100.6%
EBITDA Growth %45.3%72.58%30.03%-14.25%8.07%-35.1%-104.45%-61.35%-13.13%-
D&A (Non-Cash Add-back)15.33M17.83M19.26M22.23M20.92M13.95M8.47M7.79M6M5.8M
EBIT-45.07M-47.68M-148.01M-211.5M-196.13M-207.3M-152.82M-78.39M-49.76M-43.63M
Net Interest Income1.21M-2.33M2.95M1.73M-182K1.67M6.59M9.79M3.31M1.64M
Interest Income10.25M9.44M14.53M15.53M4.06M1.67M6.59M9.79M3.31M1.64M
Interest Expense9.04M11.78M11.58M13.8M4.24M00000
Other Income/Expense-22.54M-2.33M2.95M1.73M-182K1.67M6.59M9.79M3.31M1.64M
Pretax Income-70.75M-59.46M-159.59M-225.3M-200.37M-207.3M-146.23M-68.61M-46.45M-42.83M
Pretax Margin %-23.74%-21.47%-89.18%-132.32%-108.13%-134.31%-148.63%-80.65%-83.44%-111.4%
Income Tax0000000000
Effective Tax Rate %0%0%0%0%0%0%0%0%0%0%
Net Income-70.52M-59.5M-159.49M-225.25M-200.19M-207.28M-146.23M-68.61M-46.45M-42.83M
Net Margin %-23.66%-21.48%-89.12%-132.29%-108.03%-134.3%-148.63%-80.65%-83.44%-111.4%
Net Income Growth %11.42%62.69%29.19%-12.52%3.42%-41.75%-113.14%-47.71%-8.44%-
Net Income (Continuing)-70.75M-59.46M-159.59M-225.3M-200.37M-207.3M-146.23M-68.61M-46.45M-42.83M
Discontinued Operations0000000000
Minority Interest7.68M6.21M-224K-121K-67K110K0000
EPS (Diluted)-0.38-0.39-1.08-1.56-1.40-1.46-1.06-0.47-0.44-0.41
EPS Growth %16.51%63.89%30.77%-11.43%4.11%-37.74%-125.53%-6.82%-7.32%-
EPS (Basic)--0.39-1.08-1.56-1.40-1.46-1.06-0.47-0.44-0.41
Diluted Shares Outstanding186.88M151.72M147.1M144.38M142.52M140.35M131.22M124.34M105.43M105.43M
Basic Shares Outstanding160.4M151.72M147.1M144.38M142.52M140.35M131.22M124.34M105.43M105.43M
Dividend Payout Ratio----------

Key Metrics

Growth RegimeExpanding
ProfitabilityStrained
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Persistent operating losses and leverage

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Re-Accelerating Off a Low Base

Based on reported quarterly figures, ADPT's revenue rose from $43.2M in 2024Q2 to $83.9M in 2026Q3, with the latest quarter showing year-over-year growth of roughly 55 percent that suggests the top line is inflecting meaningfully upward.

The growth pattern appears to be driven at least partly by lumpy collaboration and milestone revenue, which may explain the sharp swing between the 2025Q3 peak of $94.0M and the subsequent sequential decline to $71.6M. Investors should separate recurring clonoSEQ volume growth from one-time partnership payments before extrapolating the current rate. The durability of expansion remains unproven until several quarters show sequential growth without a large non-recurring contribution.

Gross Margin Holds While Operating Margin Turns Near Breakeven

As reported in the quarterly income statements, gross margin climbed from 55.3% in 2024Q2 to 76.2% in 2026Q3, while operating margin improved from -109.6% to -0.5%, indicating substantial structural progress.

The gross margin expansion suggests that the fixed laboratory cost base is being absorbed by higher test volumes, consistent with a high-value diagnostic model. The latest quarter's near-zero operating margin is encouraging, though it coincides with a revenue spike that may not repeat. Sustainability depends on whether gross margins remain above 70 percent through quarters with lower milestone contribution.

Operating Leverage Emerging but Unconfirmed

According to the reported figures, operating expenses of roughly $64M in 2026Q3 against $64.0M of gross profit left operating income near breakeven, versus an operating loss of $33.8M in 2024Q4 when gross profit was far smaller.

Operating income appears to be scaling faster than the operating cost base over the last six quarters, which is the core signature of positive operating leverage. However, R&D and SG&A have stayed in the $40M to $48M combined range even as revenue doubled, suggesting discipline but also that the cost base has not been fully reset. Whether this leverage persists depends on whether the latest quarter reflects a durable run rate.

Net Income Swing Warrants Verification

Reported net income moved from a $-46.2M loss in 2024Q2 to $2.9M in 2026Q3, but the latest quarter's net margin of 3.4% sits well above its operating margin of -0.5%, which warrants investigation of non-operating items.

The gap between operating income and net income in 2026Q3 suggests non-operating gains, such as interest income or other items, may have contributed to the reported profit. Stock-based compensation of $10.4M in the latest quarter is a meaningful non-cash charge that flatters cash economics relative to GAAP net income in some periods. Investors should review the filing to confirm the composition of the positive bottom-line result before treating it as operating profitability.

Cost Base Stable While Revenue Scales

Based on reported figures, cost of revenue fell as a share of sales from roughly 45 percent in 2024Q2 to 23.8 percent in 2026Q3, with R&D and SG&A held in a relatively narrow band throughout the period.

The stable absolute spending on R&D and SG&A, despite doubling revenue, suggests management has prioritized expense discipline over aggressive reinvestment. This restraint supports margin improvement but may also constrain the pace of therapeutic pipeline development. Investors should monitor whether R&D spending is sustained at current levels, since underinvestment in the immune medicine platform could weaken the long-term moat.

Profitability Claim Not Yet Reconciled

Trailing margins of -20.6% operating and -21.5% net remain deeply negative, which conflicts with management's framing of total company profitability and suggests the bull case may rest on adjusted or single-quarter measures.

A single profitable quarter driven by revenue lumpiness does not establish a sustainable earnings base, and the 2025Q3 peak was followed by a sharp reversal. Elevated leverage with a debt-to-equity ratio of 1.25 and an ROE of -27.8% leaves limited margin for error if revenue slips again. Investors should treat the profitability inflection as a hypothesis to be confirmed through consecutive GAAP-profitable quarters.

ADPT — Frequently Asked Questions

Quick answers to the most common questions about buying ADPT stock.

What was Adaptive Biotechnologies Corporation's (ADPT) revenue in 2025?

For fiscal year 2025, Adaptive Biotechnologies Corporation (ADPT) reported total revenue of $277.0M. This represents a 620.4% increase compared to $38.4M in 2017.

Is Adaptive Biotechnologies Corporation (ADPT) profitable?

Adaptive Biotechnologies Corporation (ADPT) reported a net loss of $59.5M for the fiscal year ending 2025.

What is Adaptive Biotechnologies Corporation's operating profit margin?

Adaptive Biotechnologies Corporation (ADPT) reported an operating income of $-57.1M, resulting in an operating profit margin of -20.6%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Adaptive Biotechnologies Corporation's gross profit and gross margin?

Adaptive Biotechnologies Corporation (ADPT) generated $205.6M in gross profit for the year, representing a gross profit margin of 74.2%. This demonstrates the company's core pricing power and production efficiency.